{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:53:33Z","timestamp":1793710413929,"version":"4.6.1"},"reference-count":89,"publisher":"Massachusetts Medical Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,3,4]]},"DOI":"10.1056\/nejmra2027612","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T17:02:00Z","timestamp":1614790920000},"page":"842-858","source":"Crossref","is-referenced-by-count":1167,"title":["Diffuse Large B-Cell Lymphoma"],"prefix":"10.1056","volume":"384","author":[{"given":"Laurie H.","family":"Sehn","sequence":"first","affiliation":[{"name":"From the BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada (L.H.S.); and the Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (G.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"From the BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada (L.H.S.); and the Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (G.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","volume":"346","author":"Rosenwald A","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.12075054","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications.","volume":"37","author":"Wright GW","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020;37(4):551-568.e14.32289277","journal-title":"Cancer Cell"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.","volume":"24","author":"Chapuy B","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24:679-690.29713087","journal-title":"Nat Med"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma.","volume":"37","author":"Ennishi D","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 2019;37:190-201.30523716","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.25113753","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_7_2","unstructured":"Swerdlow SH Campo E Harris NL Jaffe ES Pileri SA Thiele J. WHO classification of tumors of the haematopoietic and lymphoid tissues. Lyon France: International Agency for Research on Cancer 2017."},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults.","volume":"378","author":"Dierickx D","year":"2018","unstructured":"Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 2018;378:549-562.29414277","journal-title":"N Engl J Med"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas.","volume":"359","author":"Lenz G","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.19038878","journal-title":"N Engl J Med"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.","volume":"33","author":"Scott DW","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015;33:2848-2856.26240231","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"29","author":"Meyer PN","year":"2011","unstructured":"Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-207.21135273","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.","volume":"37","author":"Rosenwald A","year":"2019","unstructured":"Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2019;37:3359-3368.31498031","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.","volume":"131","author":"Scott DW","year":"2018","unstructured":"Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018;131:2060-2064.29475959","journal-title":"Blood"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.","volume":"124","author":"Petrich AM","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014;124:2354-2361.25161267","journal-title":"Blood"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Johnson NA","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-3459.22851565","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.","volume":"2014","author":"Cerhan JR","year":"2014","unstructured":"Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:15-25.25174023","journal-title":"J Natl Cancer Inst Monogr"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ng.3105","article-title":"Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.","volume":"46","author":"Cerhan JR","year":"2014","unstructured":"Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 2014;46:1233-1238.25261932","journal-title":"Nat Genet"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.","volume":"32","author":"Barrington SF","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048-3058.25113771","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489-2496.27574190","journal-title":"Blood"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy.","volume":"135","author":"Vercellino L","year":"2020","unstructured":"Vercellino L, Cottereau A-S, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood 2020;135:1396-1405.31978225","journal-title":"Blood"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.","volume":"29","author":"Sehn LH","year":"2011","unstructured":"Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29:1452-1457.21383296","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/bloodadvances.2019001261","article-title":"Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.","volume":"4","author":"Rutherford SC","year":"2020","unstructured":"Rutherford SC, Herold M, Hiddemann W, et al. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood Adv 2020;4:1589-1593.32298429","journal-title":"Blood Adv"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.","volume":"118","author":"Casasnovas R-O","year":"2011","unstructured":"Casasnovas R-O, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011;118:37-43.21518924","journal-title":"Blood"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma.","volume":"36","author":"Kurtz DM","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018;36:2845-2853.30125215","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"32","author":"Maurer MJ","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014;32:1066-1073.24550425","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma.","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 1993;329:987-994.8141877","journal-title":"N Engl J Med"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.","volume":"135","author":"Ruppert AS","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020;135:2041-2048.32232482","journal-title":"Blood"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.","volume":"109","author":"Sehn LH","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.17105812","journal-title":"Blood"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.","volume":"123","author":"Zhou Z","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842.24264230","journal-title":"Blood"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma.","volume":"339","author":"Miller TP","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med 1998;339:21-26.9647875","journal-title":"N Engl J Med"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.11807147","journal-title":"N Engl J Med"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.","volume":"378","author":"R\u00e9cher C","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858-1867.22118442","journal-title":"Lancet"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303.","volume":"37","author":"Bartlett NL","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303. J Clin Oncol 2019;37:1790-1799.30939090","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma.","volume":"35","author":"Vitolo U","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2017;35:3529-3537.28796588","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).","volume":"9","author":"Pfreundschuh M","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.18226581","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2018-99-116845","article-title":"No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study.","volume":"132","author":"Sehn LH","year":"2018","unstructured":"Sehn LH, Congiu A, Culligan DJ, et al. No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study. Blood 2018;132:Suppl 1:783-783. abstract.","journal-title":"Blood"},{"key":"e_1_3_5_37_2","article-title":"Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.","author":"Freeman CL","year":"2020","unstructured":"Freeman CL, Savage KJ, Villa D, et al. Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Blood 2020 September 1 (Epub ahead of print).32871586","journal-title":"Blood"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.","volume":"20","author":"Davies A","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019;20:649-662.30948276","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma.","volume":"35","author":"Leonard JP","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 2017;35:3538-3546.28862883","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma.","volume":"37","author":"Younes A","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37:1285-1295.30901302","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_41_2","article-title":"Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup study ECOG-ACRIN E1412.","author":"Nowakowski GS","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup study ECOG-ACRIN E1412. J Clin Oncol 2021 February 8 (Epub ahead of print).33555941","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_42_2","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma.","author":"Nowakowski GS","unstructured":"Nowakowski GS, Chiappella A, Gascoyne R, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol (in press).","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.","volume":"24","author":"Habermann TM","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.16754935","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.","volume":"34","author":"Crump M","year":"2016","unstructured":"Crump M, Lepp\u00e4 S, Fayad L, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol 2016;34:2484-2492.27217449","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdx764","article-title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.","volume":"29","author":"Witzig TE","year":"2018","unstructured":"Witzig TE, Tobinai K, Rigacci L, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol 2018;29:707-714.29253068","journal-title":"Ann Oncol"},{"key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"35","author":"Thieblemont C","year":"2017","unstructured":"Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2017;35:2473-2481.28426350","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials.","volume":"36","author":"Maurer MJ","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 2018;36:1603-1610.29672223","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736.","volume":"34","author":"Stephens DM","year":"2016","unstructured":"Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol 2016;34:2997-3004.27382104","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_49_2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.","volume":"394","author":"Poeschel V","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 2019;394:2271-2281.31868632","journal-title":"Lancet"},{"key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.","volume":"131","author":"Lamy T","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 2018;131:174-181.29061568","journal-title":"Blood"},{"key":"e_1_3_5_51_2","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001.","volume":"38","author":"Persky DO","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 2020;38:3003-3011.32658627","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_52_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2019-128722","article-title":"Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC).","volume":"134","author":"Sehn LH","year":"2019","unstructured":"Sehn LH, Scott DW, Villa D, et al. Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood 2019;134:Suppl 1:401-401. abstract.","journal-title":"Blood"},{"key":"e_1_3_5_53_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.","volume":"12","author":"Peyrade F","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.21482186","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_3_5_54_2","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.","volume":"4","author":"Peyrade F","year":"2017","unstructured":"Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol 2017;4(1):e46-e55.28041583","journal-title":"Lancet Haematol"},{"key":"e_1_3_5_55_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.","volume":"32","author":"Fields PA","year":"2014","unstructured":"Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 2014;32:282-287.24220559","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_56_2","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.","author":"Moccia AA","unstructured":"Moccia AA, Schaff K, Freeman C, et al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Adv (in press).","journal-title":"Blood Adv"},{"key":"e_1_3_5_57_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.","volume":"133","author":"Klanova M","year":"2019","unstructured":"Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood 2019;133:919-926.30617197","journal-title":"Blood"},{"key":"e_1_3_5_58_2","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","article-title":"Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.","volume":"127","author":"Savage KJ","year":"2016","unstructured":"Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016;127:2182-2188.26834242","journal-title":"Blood"},{"key":"e_1_3_5_59_2","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP.","volume":"34","author":"Schmitz N","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34:3150-3156.27382100","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_60_2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.","volume":"111","author":"Cheah CY","year":"2014","unstructured":"Cheah CY, Herbert KE, O\u2019Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 2014;111:1072-1079.25072255","journal-title":"Br J Cancer"},{"key":"e_1_3_5_61_2","doi-asserted-by":"crossref","unstructured":"Orellana-Noia V Reed DR Sen JM et al. CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions. Blood 2020;136:Suppl 1:478-478. abstract.","DOI":"10.1182\/blood-2020-134798"},{"key":"e_1_3_5_62_2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","article-title":"Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.","volume":"105","author":"Eyre TA","year":"2020","unstructured":"Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica 2020;105:1914-1924.31488560","journal-title":"Haematologica"},{"key":"e_1_3_5_63_2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800-1808.28774879","journal-title":"Blood"},{"key":"e_1_3_5_64_2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"37","author":"Wang Y","year":"2019","unstructured":"Wang Y, Farooq U, Link BK, et al. Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2019;37:1819-1827.31170029","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_65_2","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.","volume":"32","author":"Crump M","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490-3496.25267740","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_66_2","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"Gisselbrecht C","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.20660832","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_67_2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy: a phase II Lymphoma Study Association trial.","volume":"98","author":"Mounier N","year":"2013","unstructured":"Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy: a phase II Lymphoma Study Association trial. Haematologica 2013;98:1726-1731.23753028","journal-title":"Haematologica"},{"key":"e_1_3_5_68_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.","volume":"396","author":"Abramson JS","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839-852.32888407","journal-title":"Lancet"},{"key":"e_1_3_5_69_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017;377:2531-2544.29226797","journal-title":"N Engl J Med"},{"key":"e_1_3_5_70_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45-56.30501490","journal-title":"N Engl J Med"},{"key":"e_1_3_5_71_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma.","volume":"29","author":"Jurczak W","year":"2018","unstructured":"Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol 2018;29:1266-1272.29444231","journal-title":"Ann Oncol"},{"key":"e_1_3_5_72_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.","volume":"21","author":"Salles G","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978-988.32511983","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_73_2","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma.","author":"Hamadani M","year":"2020","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood 2020 November 19 (Epub ahead of print).33211842","journal-title":"Blood"},{"key":"e_1_3_5_74_2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression.","volume":"125","author":"Jacobsen ED","year":"2015","unstructured":"Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood 2015;125:1394-1402.25573987","journal-title":"Blood"},{"key":"e_1_3_5_75_2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.","volume":"16","author":"Palanca-Wessels MCA","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015;16:704-715.25925619","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_76_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.","volume":"38","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155-165.31693429","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_77_2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma.","volume":"127","author":"Viardot A","year":"2016","unstructured":"Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 2016;127:1410-1416.26755709","journal-title":"Blood"},{"key":"e_1_3_5_78_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines.","volume":"134","author":"Schuster S","year":"2019","unstructured":"Schuster S, Bartlett N, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 2019;134:Suppl 1:6-6. abstract.","journal-title":"Blood"},{"key":"e_1_3_5_79_2","unstructured":"Hutchings M Morschhauser F Iacoboni G et al. Glofitamab a novel bivalent CD20 targeting T-cell engaging bispecific antibody induces durable complete remissions in relapsed\/refractory B-cell lymphoma: a phase I trial. J Clin Oncol (in press)."},{"key":"e_1_3_5_80_2","doi-asserted-by":"crossref","unstructured":"Bannerji R Allan JA Arnason JE et al. Odronextamab (REGN1979) a human CD20 x CD3 bispecific antibody induces durable complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma including patients refractory to CAR T therapy. Presented at the 62nd American Society of Hematology virtual Annual Meeting and Exposition December 5\u20138 2020. abstract.","DOI":"10.1182\/blood-2020-136659"},{"key":"e_1_3_5_81_2","doi-asserted-by":"crossref","unstructured":"Hutchings M Mous R Clausen MR et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes including patients with prior CAR-T therapy: updated dose escalation data. Blood 2020;136:Suppl 1:45-46. abstract.","DOI":"10.1182\/blood-2020-133820"},{"key":"e_1_3_5_82_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.","volume":"21","author":"Wilson WH","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922-926.26193343","journal-title":"Nat Med"},{"key":"e_1_3_5_83_2","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma.","volume":"23","author":"Czuczman MS","year":"2017","unstructured":"Czuczman MS, Trn\u011bn\u00fd M, Davies A, et al. A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 2017;23:4127-4137.28381416","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_84_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma.","volume":"35","author":"Davids MS","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2017;35:826-833.28095146","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_5_85_2","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.","volume":"7","author":"Kalakonda N","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-e522.32589977","journal-title":"Lancet Haematol"},{"key":"e_1_3_5_86_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study.","volume":"37","author":"Ansell SM","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol 2019;37:481-489.30620669","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_87_2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma.","volume":"379","author":"Advani R","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med 2018;379:1711-1721.30380386","journal-title":"N Engl J Med"},{"key":"e_1_3_5_88_2","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1182\/blood-2018-99-113411","article-title":"Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL).","volume":"132","author":"Ribrag V","year":"2018","unstructured":"Ribrag V, Morschhauser F, McKay P, et al. Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Blood 2018;132:Suppl 1:4196-4196. abstract.","journal-title":"Blood"},{"key":"e_1_3_5_89_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:31-42.30518502","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_90_2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.","volume":"37","author":"Lin JK","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol 2019;37:2105-2119.31157579","journal-title":"J Clin Oncol"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra2027612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:37:37Z","timestamp":1711485457000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra2027612"}},"subtitle":[],"editor":[{"given":"Dan L.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":89,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3,4]]}},"alternative-id":["10.1056\/NEJMra2027612"],"URL":"https:\/\/doi.org\/10.1056\/nejmra2027612","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}